Abstract:Breast cancer is the most common female malignancy worldwide and the prognosis of triple-negative breast cancer (TNBC) and advanced breast cancer patients is unsatisfying. The exploration of novel prognostic indicators and appropriate targets is crucial for improving the treatment outcomes of breast cancer patients. The cell division cycle protein 14B (CDC14B) is known for its roles in cell cycle control, but its expression status and molecular function in breast cancer is unknown. This study explores the expression patterns and clinical values of CDC14B in breast cancer tissues. For this research, the authors downloaded gene microarrays and RNA sequencing datasets to examine the expression levels of CDC14B in 5218 breast cancer tissues, comparing them to the expression levels in 1176 normal breast tissues. The relationships between CDC14B and clinicopathologic characteristics of breast cancer were also addressed. The mutation conditions of CDC14B were then clarified using cBioPortal. Finally, differentially expressed genes and co-expressed genes related to CDC14B were filtered using the Limma-Voom package. These genes were intersected to conduct functional annotations and to construct a protein-protein interaction network. It was observed that CDC14B was significantly downregulated in breast cancer tissues but not in normal breast tissues (standardized mean difference= -1.17 [-1.50--0.85], area under the curve = 0.88). In addition, CDC14B downregulation was correlated with the poor prognosis of TNBC patients (hazard ratios < 1; p < 0.05). Amplification was detected to be the most frequent alteration of CDC14B. The presence of this alteration forecasted unfavourable overall survival outcomes in breast cancer patients (p < 0.05). Dysregulated genes that co-expressed with CDC14B were pivotal in cell cycle (namely mitotic-nuclear division and DNA packaging complex) and cancer-related signaling pathways (namely the peroxisome proliferators activated receptor [PPAR] signalling pathway and the AMP-activated protein kinase [AMPK] signalling pathway). Moreover, the genes ADIPOQ and CCNE2 were identified as two promising prognostic factors in breast cancer. In summary, CDC14B was downregulated in breast cancer tissue and may be a promising hallmark in TNBC patients. The dysregulated genes co-expressed with CDC14B may play an important role in the development of breast cancer through PPAR and AMPK signalling pathways.

Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer

ECRG4 Acts As a Tumor Suppressor Gene Frequently Hypermethylated in Human Breast Cancer.

The tumor-promoting function of ECRG4 in papillary thyroid carcinoma and its related mechanism

Telomere-Associated Gene Signatures Correlate with Prognosis, Tumor Microenvironment, and Chemosensitivity in Breast Cancer.

Expression and Epigenetic Silencing of Ecrg4 Gene in Breast Cancer

Downregulated ECRG4 is Associated with Poor Prognosis in Renal Cell Cancer and is Regulated by Promoter DNA Methylation

Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation

[Expression and Function of ECRG4 in Hepatocellular Carcinoma].

ECRG4 As a Novel Tumor Suppressor Gene Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo

Downregulated ECRG4 is Correlated with Lymph Node Metastasis and Predicts Poor Outcome for Nasopharyngeal Carcinoma Patients

ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma

Expression of ECRG4, a Novel Esophageal Cancer-Related Gene, Downregulated by CpG Island Hypermethylation in Human Esophageal Squamous Cell Carcinoma

ECRG4 Inhibits Growth and Invasiveness of Squamous Cell Carcinoma of the Head and Neck in Vitro and in Vivo

ECRG4: a New Potential Target in Precision Medicine

The Role of Early Growth Response Family Members 1–4 in Prognostic Value of Breast Cancer

EIF4G1 is a Potential Prognostic Biomarker of Breast Cancer

Regulator of G-protein signaling 4: a novel tumor suppressor with prognostic significance in non-small cell lung cancer.

Expression and prognostic analyses of early growth response proteins (EGRs) in human breast carcinoma based on database analysis

Downregulation Of Cdc14b In 5218 Breast Cancer Patients: A Novel Prognosticator For Triple-Negative Breast Cancer

Elevated Risk of Adverse Prognosis in Patients with T2-3 Stage Breast Cancer Exhibiting Non-Pathological Complete Response Following Neoadjuvant Chemotherapy: Significance of Regenerating Islet-Derived Family Member 4

Loss, mutation and deregulation of L3MBTL4 in breast cancers